abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 12일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제110회 대한화학회 학술발표회, 총회 및 기기전시회 안내 CrystalGenomics: from Protein Structure to New Drug

등록일
2012년 9월 10일 14시 08분 39초
접수번호
1762
발표코드
MEDI-2 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 15시 : 20분
발표형식
심포지엄
발표분야
의약화학 - Medicinal Ventures in Korea
저자 및
공동저자
노성구
크리스탈지노믹스(주), Korea
CrystalGenomics Inc. is a clinical stage biopharmaceutical company with protein structure based drug discovery and clinical development capabilities, headquartered in Seoul, Korea with a US presence for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California and publicly traded on KOSDAQ exchange (Korea). CrystalGenomics is dedicated to the discovery and development of novel pharmaceuticals in areas of infectious disease, cancer, and inflammatory diseases. The company’s capabilities have been validated thru prestigious publications including a cover page on nature for scientific accomplishment (2003), R&D collaborations with prominent pharmaceutical companies including AstraZeneca (2010), and a joint venture deal with ProQuest Investments involving a very early stage asset (2008). The Company’s lead development candidate is a next generation NSAID, CG100649 with a novel mechanism of suppressing COX-2 as well as carbonic anhydrase enzymes for improved cardiovascular, gastrointestinal, and renal safety profiles which is in preparation of Phase 3 study for osteoarthritis. Additionally, its novel HDAC inhibitor, CG200745 for cancer is in Phase 1, and a novel antibiotic candidate, CG400549 for MRSA infection, is in Phase 2a Study in the US.

상단으로